Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer

BACKGROUND: Trastuzumab-based therapies are the therapeutic option for HER2 positive (HER2+) breast cancer. HER2 amplification is the only biomarker validated for trastuzumab-based therapies. However, a proportion of tumors become refractory during treatment course. For this reason, the finding of n...

Descripción completa

Detalles Bibliográficos
Autores principales: Díaz-Gil, Laura, Brasó-Maristany, Fara, Locatelli, Claudriana, Centa, Ariana, Győrffy, Balász, Ocaña, Alberto, Prat, Aleix, Pandiella, Atanasio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496101/
https://www.ncbi.nlm.nih.gov/pubmed/34620206
http://dx.doi.org/10.1186/s13046-021-02098-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496101/
https://www.ncbi.nlm.nih.gov/pubmed/34620206
http://dx.doi.org/10.1186/s13046-021-02098-z

Ejemplares similares